Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2014 May 13;110(10):2489-95. doi: 10.1038/bjc.2014.169. Epub 2014 Apr 10.

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.

Author information

  • 1Department of Oncology-Pathology, Karolinska Institutet, CCK R8:03, Karolinska University Hospital, Solna, S-17176 Stockholm, Sweden.
  • 2Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, Tomtebodavägen 23, S-17165 Solna, Sweden.

Abstract

BACKGROUND:

Disseminated cutaneous malignant melanoma (CMM) is commonly unresponsive to standard chemotherapies, and there are as yet no predictive markers of therapy response.

METHODS:

In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response. We performed quantitative protein profiling using tandem mass spectrometry and compared the proteome differences between responders (R) and non-responders (NR), matched for age, gender and histopathological type of CMM.

RESULTS:

Biological pathway analyses showed several signalling pathways differing between R vs NR, including Rho signalling. Gene expression profiling data was available for a subset of the samples, and the results were compared with the proteomics data. Four proteins with differential expression between R and NR were selected for technical validation by immunoblotting (ISYNA1, F13A1, CSTB and S100A13), and CSTB and S100A13 were further validated on a larger sample set by immunohistochemistry (n=48). The calcium binding protein S100A13 was found to be significantly overexpressed in NR compared with R in all analyses performed.

CONCLUSIONS:

Our results suggest that S100A13 is involved in CMM resistance to DTIC/TMZ.

PMID:
24722184
[PubMed - indexed for MEDLINE]
PMCID:
PMC4021518
[Available on 2015/5/13]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk